EU: No SPCs For New Uses OF Existing Drugs
Ruling Reverses Court’s 2012 Decision
A judgment by the Court of Justice of the EU is bad news for innovators seeking supplementary protection certificates to protect new indications for their products, but it could offer new opportunities for generic firms.
You may also be interested in...
The pharmaceutical industry will be watching carefully as the EU Court of Justice deliberates on whether to deny or widen the granting of supplementary protection certificates on new therapeutic indications of authorized medicines.
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.